Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | TGM2 | P21980 | 5/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600836 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29400961 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178701 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29401249 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29391986 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25358347 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29350360 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178771 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL21462054 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25356530 | 0.99 | KMT2A (0.59) | KMT2AMDM2TGM2TLR2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | PEPTIAID INC (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4317174-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | Peptiaid Inc (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022202816-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | ペプチエイド株式会社 | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | NGLY1, VIP, HM13 | KMT2A 2534/4885MDM2 3700/4885TGM2 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.